CLINICAL TRIALS PROFILE FOR TRIMETHOPRIM HYDROCHLORIDE

505(b)(2) Clinical Trials for TRIMETHOPRIM HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Combination	NCT03431168 ↗	A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV	Active, not recruiting	University of Alabama at Birmingham	Phase 2	2018-03-07	More than 3 billion people worldwide are at risk of acquiring malaria and pregnant women living with HIV in Africa are at particular risk. An effective prophylaxis regimen capable of preventing malaria and other common perinatal infections would have great potential to improve adverse birth outcomes. The purpose of this randomized controlled trial is to evaluate a new combination prophylaxis regimen in pregnant women with HIV in Cameroon to determine its efficacy and safety.
OTC	NCT05055544 ↗	Bearberry in the Treatment of Cystitis	Not yet recruiting	University of Pecs	N/A	2021-10-01	The goal of this study is to assess the efficacy of bearberry in uncomplicated cystitis. Uncomplicated cystitis is a disease related to the infection of the urinary bladder. Typical symptoms are dysuria, urinary urgency, and frequent voiding of small volumes. Urinary tract infections are frequent in women, usually treated with antibiotics, since the disease is usually caused by bacteria. Fosfomycin is a frequently used antibiotic for the treatment of uncomplicated cystitis. This medicine is typically prescribed by MDs. However, since uncomplicated cystitis is quite frequent, not all patients visit the doctor when experiencing the symptoms of this disease. The use of over-the-counter products (medicines and food supplements) to alleviate the symptoms is common. One of the most frequently used medicinal plants for this purpose is bearberry. Bearberry is a medicinal plant traditionally used for the treatment of cystitis. Its use is accepted by the European Medicine Agency as traditional herbal medicinal product for relief of symptoms of mild recurrent lower urinary tract infections such as burning sensation during urination and/or frequent urination in women. Although the experience gained during the traditional use and the laboratory experiments support the supposed beneficial effect of bearberry, its clinical efficacy has not been confirmed in well-designed clinical trials in comparison with standard antibiotic therapy. In this study, the efficacy of bearberry will be assessed in comparison with fosfomycin. Premenopausal women experiencing the symptoms of uncomplicated cystitis will be randomly divided into two groups. Since it will be a double-blind trial, neither the participants nor the experimenters will know who is receiving a particular treatment. In group A, patients will receive a single dose of fosfomycin powder dissolved in water and 2 placebo tablets three times a day for 7 days. In group B, patients will receive a single dose of placebo powder dissolved in water and 2 bearberry tablets three times a day for 7 days. At the beginning of the study (day 0) and on day 7, patients will be asked to fill in a questionnaire concerning their symptoms. At the same times, urine specimens will be collected to inspect the presence of bacteria in the urine. The primary goal of the trial is to assess the improvement of symptoms of uncomplicated cystitis after 7 days of treatment with the intention to analyze whether treatment with bearberry is at least as effective as fosfomycin therapy is. This will be achieved by using a validated questionnaire (Acute Cystitis Symptom Score). The presence of bacteria in urine and the frequency and severity of side effects will also be recorded and compared. During a 90-days follow-up of this study, the recurrence of urinary tract infections will be analyzed. This study will deliver important data on the efficacy and safety of bearberry in the treatment of uncomplicated cystitis.

All Clinical Trials for TRIMETHOPRIM HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000640 ↗	A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS	Completed	Glaxo Wellcome	Phase 3	1969-12-31	To evaluate the effectiveness of two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard treatment program of sulfamethoxazole/trimethoprim (SMX/TMP) to assess the tolerance of these two alternative treatments as compared to the standard treatment of SMX/TMP. Per 09/09/92 amendment, to assess the efficacy and tolerance of these two alternative treatments in patients who are intolerant to SMX/TMP. The type of treatment being studied has the advantages of wide applicability throughout the world (including developing countries) and low cost. An oral treatment is more accessible to patients than drugs given by injection or by inhalation.
NCT00000640 ↗	A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS	Completed	Jacobus Pharmaceutical	Phase 3	1969-12-31	To evaluate the effectiveness of two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard treatment program of sulfamethoxazole/trimethoprim (SMX/TMP) to assess the tolerance of these two alternative treatments as compared to the standard treatment of SMX/TMP. Per 09/09/92 amendment, to assess the efficacy and tolerance of these two alternative treatments in patients who are intolerant to SMX/TMP. The type of treatment being studied has the advantages of wide applicability throughout the world (including developing countries) and low cost. An oral treatment is more accessible to patients than drugs given by injection or by inhalation.
NCT00000640 ↗	A Phase III Comparative Study of Dapsone / Trimethoprim and Clindamycin / Primaquine Versus Sulfamethoxazole / Trimethoprim in the Treatment of Mild-to-Moderate PCP in Patients With AIDS	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	To evaluate the effectiveness of two oral treatments for mild to moderate Pneumocystis carinii pneumonia (PCP): dapsone/trimethoprim or clindamycin/primaquine as compared to a standard treatment program of sulfamethoxazole/trimethoprim (SMX/TMP) to assess the tolerance of these two alternative treatments as compared to the standard treatment of SMX/TMP. Per 09/09/92 amendment, to assess the efficacy and tolerance of these two alternative treatments in patients who are intolerant to SMX/TMP. The type of treatment being studied has the advantages of wide applicability throughout the world (including developing countries) and low cost. An oral treatment is more accessible to patients than drugs given by injection or by inhalation.

Clinical Trial Conditions for TRIMETHOPRIM HYDROCHLORIDE

Condition Name

Condition Name for TRIMETHOPRIM HYDROCHLORIDE
Intervention	Trials
HIV Infections	36
Pneumonia, Pneumocystis Carinii	27
Urinary Tract Infection	11

Condition MeSH

Condition MeSH for TRIMETHOPRIM HYDROCHLORIDE
Intervention	Trials
Infections	42
Pneumonia	41
HIV Infections	39

Clinical Trial Locations for TRIMETHOPRIM HYDROCHLORIDE

Trials by Country

Trials by Country for TRIMETHOPRIM HYDROCHLORIDE
Location	Trials
United States	445
Canada	21
France	16
China	16
Netherlands	12

Trials by US State

Trials by US State for TRIMETHOPRIM HYDROCHLORIDE
Location	Trials
California	35
New York	27
Pennsylvania	24
Illinois	24
Ohio	23

Clinical Trial Progress for TRIMETHOPRIM HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for TRIMETHOPRIM HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	9
PHASE2	5
PHASE1	2

Clinical Trial Status

Clinical Trial Status for TRIMETHOPRIM HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	105
RECRUITING	29
Terminated	15

Clinical Trial Sponsors for TRIMETHOPRIM HYDROCHLORIDE

Sponsor Name

Sponsor Name for TRIMETHOPRIM HYDROCHLORIDE
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	32
Glaxo Wellcome	8
University of California, San Francisco	7

Sponsor Type

Sponsor Type for TRIMETHOPRIM HYDROCHLORIDE
Sponsor	Trials
Other	255
NIH	55
Industry	53

TRIMETHOPRIM HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: April 25, 2026

Clinical Trials Update, Market Analysis and Projection: Trimethoprim Hydrochloride

Trimethoprim hydrochloride is an established, off-patent antibacterial active ingredient used in combination products (most commonly with sulfamethoxazole) for systemic infections and urinary tract indications. The clinical-trials landscape and forward market outlook are dominated by generic supply, mature resistance patterns, and procurement-driven demand rather than pipeline novelty.

What is the current clinical-trials signal for trimethoprim hydrochloride?

Clinical-trial coverage in major registries

Public clinical-trial visibility for trimethoprim hydrochloride is typically low at the single-API level because most studies evaluate combination regimens (e.g., trimethoprim-sulfamethoxazole) or incorporate trimethoprim in fixed-dose products rather than standalone trimethoprim hydrochloride. Trial activity that remains searchable in clinical registries is therefore often categorized by indication, formulation, or combination product.

Practical interpretation for investors and R&D teams

• Trial volume is expected to skew toward pharmacokinetic (PK), bioequivalence (BE), formulation, and real-world evidence studies rather than first-in-class efficacy trials.
• Competitive differentiation is less likely to come from “new chemistry” and more likely from formulation strategy, dose optimization, or regional label expansion through generic or quasi-generic entrants.
• In most jurisdictions, regulatory pathways for generic antibiotics rely on BE and established safety/efficacy, limiting the number of sponsor-led interventional studies.

Where to look for actionable trial updates

For operational monitoring, the most decision-useful fields are:

• Study status: recruiting, active, completed
• Intervention naming: whether trimethoprim is listed alone vs in combination
• Endpoints: PK/BE vs clinical outcomes
• Geography: regions with higher prescribing and procurement activity

Clinical-trial monitoring sources

• ClinicalTrials.gov registry (search by “trimethoprim hydrochloride” and by combination terms). [1]
• WHO ICTRP portal (cross-registry aggregation). [2]

What is the market structure for trimethoprim hydrochloride?

Demand drivers

Trimethoprim hydrochloride demand is tied to:

• Infectious disease prescribing for urinary tract infections and other susceptible bacterial indications.
• Antibiotic guideline cycles and local antimicrobial stewardship policies.
• Resistance prevalence that can shift usage toward alternative agents (nitrofurantoin, fosfomycin, fluoroquinolones, cephalosporins, or newer combinations) or toward combination strategies that preserve efficacy.
• Procurement economics in public tender markets, where antibiotics compete primarily on unit cost, supply reliability, and formulary acceptance.

Supply and pricing dynamics

The API is mature and broadly generics-based, producing:

• Low margin for commodity supply
• Volatility driven by raw-material availability, exchange rates, and public procurement cycles
• Consolidation pressure on smaller manufacturers due to compliance and cost of regulatory maintenance

Competitive landscape

Competitive sets typically include:

• Generic antibiotic manufacturers supplying trimethoprim alone or in fixed-dose combinations
• Finished-dose brand/regional label holders that control market access, tender placement, and distribution

Replacement and substitution risk

Key substitution vectors in many formularies:

• Nitrofurantoin and fosfomycin for uncomplicated urinary tract infections in multiple markets
• Beta-lactams and newer agents where resistance to trimethoprim is high

Resistance patterns are therefore a demand modifier, not a demand destroyer, because trimethoprim combinations can remain guideline-concordant where susceptibility holds.

How big is the market and what is the credible forecast path?

Bottom-up sizing logic (what drives the number)

Because trimethoprim hydrochloride is usually commercialized as a combination or finished-dose product, credible forecasts rely on:

1. Regional antibiotic consumption volumes (UTI and related indications)
2. Formulary share of trimethoprim-based regimens
3. Tender share in public sector procurement
4. Price per unit trends driven by generic competition

Projection method (pragmatic for a commodity API)

For an established API, the forecast shape typically follows:

• Flat-to-slight growth in volume tied to population and prescribing cycles
• Declining or flat pricing due to generics competition and tender pressure
• Growth moderation or decline where resistance reduces use

Given commodity behavior, the expected outcome is:

• Market value growth lagging volume growth
• Regional divergence based on resistance and reimbursement policy

Forward-looking range for market value and volume (directional)

A directional projection for trimethoprim hydrochloride is:

• Volume: low single-digit CAGR range (driven by UTI incidence and ongoing use in susceptible populations)
• Value: flat to low single-digit CAGR range (driven by pricing pressure offsetting modest volume gains)

This is the typical pattern for off-patent antibiotic APIs unless there is a major guideline shift or supply disruption.

What regulatory and payer factors shape uptake?

Regulatory baseline

In many markets, trimethoprim hydrochloride is an approved antibiotic with established safety documentation. New entries often proceed through:

• Generic authorization via bioequivalence frameworks
• Label updates via supplemental submissions rather than new clinical efficacy programs

Stewardship and reimbursement

Uptake depends on:

• Antimicrobial stewardship interventions that restrict broad use
• Reimbursement rules that steer clinicians toward preferred agents
• Local resistance surveillance results that update susceptibility assumptions in guidelines

These factors drive the share of trimethoprim-based therapy across indications and therefore materially influence market growth even without changes to the API.

What are the most likely scenario outcomes over the next 3 to 5 years?

Scenario A: Stable stewardship, stable susceptibility

• Trimethoprim combination regimens maintain a consistent share in UTI and susceptible infections.
• Market value grows slowly as unit prices stabilize after periodic tender-driven resets.
• Clinical-trial activity stays dominated by BE and observational studies.

Scenario B: Resistance pressure increases in key geographies

• Clinicians reduce trimethoprim-based use in favor of alternatives.
• Market volume declines modestly; value declines faster due to downward substitution into lower-cost alternatives or reduced tender allocations.
• Trial activity remains low but shifts toward comparative effectiveness and PK in specific subpopulations.

Scenario C: Supply constraints or manufacturing consolidation

• Short-term price spikes and tender reallocation can temporarily lift value.
• Long-term growth is still limited by generics penetration once supply normalizes.

Key diligence checklist for investors and R&D

Use this checklist to separate “noise” from investable signal:

• Registry search hygiene: track both “trimethoprim hydrochloride” and combination regimen terms to capture the true trial footprint. [1,2]
• Region-by-region formulary share: prioritize countries with high UTI diagnosis rates and stable reimbursement.
• Resistance surveillance mapping: link market share changes to local antibiogram trends.
• Tender economics: monitor public procurement volumes and unit-price resets.
• Manufacturing compliance: in commodity antibiotics, compliance and supply reliability often outrank clinical differentiation.

Key Takeaways

• Trimethoprim hydrochloride is a mature, off-patent antibacterial API; clinical trial visibility is typically dominated by BE, PK, formulation, and combination-product studies rather than new efficacy programs.
• The market is procurement and guideline driven, with demand supported by ongoing UTI and susceptible-infection use but moderated by antimicrobial resistance and substitution to preferred alternatives.
• The most credible 3 to 5-year forecast pattern is flat-to-slight value growth with low single-digit volume growth, shaped by tender economics and stewardship policy.
• Investable diligence should focus on regional formulary/tender share, resistance surveillance, and manufacturing supply reliability rather than pipeline novelty.

FAQs

1. Is trimethoprim hydrochloride still used clinically?
   Yes, primarily in established regimens, most often as part of fixed-dose combination therapy.

2. Are there active clinical trials for trimethoprim hydrochloride?
   Clinical activity exists but is often reported under combination regimens or formulation/PK/BE studies rather than standalone efficacy trials. [1,2]

3. Does resistance materially affect the market?
   Yes. Resistance patterns influence guideline placement and prescribing share, which affects volume and can accelerate substitution.

4. What drives market value growth for mature antibiotic APIs?
   Tender pricing and procurement allocation, with limited upside from new clinical differentiation.

5. Where should monitoring focus for competitive decision-making?
   Clinical registries for PK/BE and formulation studies, resistance surveillance for uptake trends, and public procurement/tender pricing for market value shifts. [1,2]

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] World Health Organization. International Clinical Trials Registry Platform (ICTRP). https://trialsearch.who.int/